Chief Executive Officer
Alexandra Ellervik has a M.Sc. in Molecular Biology and was awarded a PhD in neurophysiology in 2004 at Lund University. After two years as a postdoctoral fellow at the University of Zurich in Switzerland, she was employed within the private business as project manager, business developer and marketer and also elected as board member. Dr Ellervik is currently employed as project manager at RhoVac AB and joined Selcis BioPharma 2021.
Founder and Chairman of the Board
Prof. Sterner is an organic chemist that has devoted his life to the science of biologically active secondary metabolites. He was awarded the PhD degree in 1985, and after two years as a postdoctoral fellow at the University of Bonn in Germany he got a position as a researcher at Lund University. 1990 he became lecturer in organic chemistry, and 1999 Dr Sterner was appointed Professor at Lund University. His research efforts has resulted in > 430 scientific publications in international journals, 30 patents and patent applications, and several textbooks in organic chemistry and chemical toxicology. He has acted as Head of the Department of Chemistry (2006 -2012) and Dean of the Faculty of Science (2012 – 2018).
Founder and Board Member
Margareta Nyman is Professor in Food Chemistry at the faculty of engineering in Lund. Her research is interdisciplinary and related to nutritional, chemical and engineering issues. The overall purpose of her research is related to food design for dietary prevention and has focused on dietary fibre/indigestible food components and their physico-chemical properties and how these properties can be related to nutritional effects, especially gastrointestinal health, colon short-chain fatty acid formation, bacterial gut metabolites and microbiota composition.
Founder and Board Member
PhD., Associate Professor in organic chemistry and M.Sc. chemical engineering at Lund University. He has nearly 20 years’ experience in medicinal chemistry and preclinical research and development. Currently he acting as Senior Director Medicinal Chemistry at Aqilion AB and Former Chief Scientific Officer at Respiratorius AB and Senior Research Scientist at AstraZeneca, Discovery R&D.
Christine Widstrand is Executive Vice President at LU Holding AB and responsible for the Life Science Portfolio. She holds a PhD in Analytical Chemistry from Lund University. With a background at CEO and founder of several biotech companies, she has gained over twenty years of experience in business development, venture capital raising, international sales and marketing, licensing and organizational and quality management. Dr. Widstrand is certified as a board member by Styrelseakademin and has an extensive experience in board work, both as a member and as a chairman.
Experienced drug discovery expert, brought one drug to the market